Yes our overhead is far lower. Our other "trick" is that several members of our team are multi-talented. For example Dr. Herst can do tissue culture work, formulation development, analytical chemistry, and immunochemistry.
It would seem difficult to raise that kind of money from other than big pharma or typical pharma capital market sources who would want to see a large pay-off from such an risky investment (i.e. selling it in countries which could afford it).
Best of luck in any case!